In situ hydrogel nanovaccine based on whole-cell tumor antigen efficiently activates adaptive immunity for the prevention and treatment of ovarian cancer
- 1Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China
- 2Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
Abstract
Due to the late diagnosis with widespread peritoneal metastases and frequent chemoresistance, ovarian cancer has limited survival rates and necessitates innovative therapies. Here, we present an in situ hydrogel nanovaccine (LCMP@ALG) for spatiotemporally-synchronized antigen-adjuvant delivery to stimulate robust antitumor immunity. The hydrogel continuously releases mannosylated nanoparticles LCMP which are effectively internalized by dendritic cells and actively accumulate in lymph nodes via the ligand-mediated targeting effect. Benefiting from autologous tumor cell lysates, the vaccines evade antigen-specific tolerance. LCMP can synergistically activate Toll-like receptor 4 and Toll-like receptor 9 to augment antigen processing and cross-presentation, further potentiating the activation of humoral and cellular antitumor immunity. In the mouse model, the vaccine LCMP@ALG induces specific antitumor responses as well as long-term immunological memory. When combined with Programmed cell death protein 1 blockade, LCMP@ALG demonstrates a superior efficacy in prevention and elimination of ovarian cancer.
Related
- A fluorinated poly(amino acid) nanovaccine with spatiotemporally encoded innate priming and antigen cross-presentation for tumor immunotherapy
- Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment
- Cancer nanovaccine plus doxorubicin and immune checkpoint blockade overcomes chemoresistance and delays postsurgical recurrence
- Recurrent pulmonary infection, a vicious cycle of multifactorial interactions, and prevention/treatment strategies
- Prevention of Klebsiella pneumoniae antibiotic resistance plasmid dissemination by prophylactic or simultaneous CRISPR-Cas9 treatment.
BibTeX
@article{yan2026situ,
title = {{In situ hydrogel nanovaccine based on whole-cell tumor antigen efficiently activates adaptive immunity for the prevention and treatment of ovarian cancer}},
author = {Jia Yan and Ruyi Lin and Qiyu Liu and Yatong Zhang and Hao Chen and Fan Tong and Yujun Song and Yulong Shi and Yuan Li},
journal = {Acta pharmaceutica Sinica. B},
year = {2026},
month = jul,
doi = {10.1016/j.apsb.2026.07.030},
url = {https://europepmc.org/article/PMC/PMC13730230},
note = {CC BY},
}
RIS
TY - JOUR
TI - In situ hydrogel nanovaccine based on whole-cell tumor antigen efficiently activates adaptive immunity for the prevention and treatment of ovarian cancer
AU - Jia Yan
AU - Ruyi Lin
AU - Qiyu Liu
AU - Yatong Zhang
AU - Hao Chen
AU - Fan Tong
AU - Yujun Song
AU - Yulong Shi
AU - Yuan Li
PY - 2026
DA - 2026/07/24
JO - Acta pharmaceutica Sinica. B
DO - 10.1016/j.apsb.2026.07.030
UR - https://europepmc.org/article/PMC/PMC13730230
AB - Due to the late diagnosis with widespread peritoneal metastases and frequent chemoresistance, ovarian cancer has limited survival rates and necessitates innovative therapies. Here, we present an in situ hydrogel nanovaccine (LCMP@ALG) for spatiotemporally-synchronized antigen-adjuvant delivery to stimulate robust antitumor immunity. The hydrogel continuously releases mannosylated nanoparticles LCMP which are effectively internalized by dendritic cells and actively accumulate in lymph nodes via the ligand-mediated targeting effect. Benefiting from autologous tumor cell lysates, the vaccines evade antigen-specific tolerance. LCMP can synergistically activate Toll-like receptor 4 and Toll-like receptor 9 to augment antigen processing and cross-presentation, further potentiating the activation of humoral and cellular antitumor immunity. In the mouse model, the vaccine LCMP@ALG induces specific antitumor responses as well as long-term immunological memory. When combined with Programmed cell death protein 1 blockade, LCMP@ALG demonstrates a superior efficacy in prevention and elimination of ovarian cancer.
SN - 2211-3835
SN - 2211-3843
ER -